kress

Biogen appoint new Head of Global Therapeutic Operations

pharmafile | June 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Jean-Paul Kress 

Biogen announced that Jean-Paul Kress has been appointed to the position of Executive Vice President and President, International, and Head of Global Therapeutic Operations.

Kress will be particularly responsible for worldwide commercial operations outside of the US and will perform an auxiliary role overseeing the Rare and Speciality Disease Asset teams.

He will join Biogen having had a broad experience of the pharmaceutical industry, having worked at a number of big pharma companies. Particularly, he worked at Eli Lilly early in his career before moving on to an eight-year stint at Abbott. He then moved onto become Vice President and General Manager of Gilead, France. Notably, he held the role of President and CEO of Sanofi Pasteur MSD for four years, at the vaccine business formed as part of the collaboration between Sanofi and MSD.

“Having watched Biogen excel in the neurology space, it is truly exciting to be joining such an admired and respected industry leader,” said Kress. “Biogen’s clear and unwavering commitment to neuroscience and to critically underserved patient populations is unique and extremely inspiring.”

“Jean-Paul brings deep expertise and decades of industry experience to Biogen at an important time for the company,” said Biogen CEO Michael Vounatsos. “As we seek to optimize our commercial function in support of our investigational compounds and build upon the leadership position of our current therapies, I believe that Jean-Paul’s strategic vision and sharp customer focus will help ensure that patients around the world gain access to transformative therapies.”

Related Content

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …

Biogen’s biosimilar Tofidence approved by FDA

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …

money_pills_2

Biogen to acquire Reata Pharmaceuticals

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which …

Latest content